**Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced Urothelial Carcinoma: the ARON-2 study**

**Matteo Santoni1, Zin W. Myint2**, Thomas Büttner3, Hideki Takeshita4, Yohei Okada4, **Elaine T Lam5,** Zsófia Küronya6**, Deniz Tural7, Renate Pichler8, Enrique Grande9,** Simon J Crabb10, Francesco Massari11**\*,** Sarah Scagliarini12, **Roberto Iacovelli13,** Nuno Vau14, Umberto Basso15, Javier Molina-Cerrillo16**, Luca Galli17, Aristotelis Bamias18, Ugo De Giorgi19, Paolo Andrea Zucali20,21, Mimma Rizzo22, Emmanuel Seront23, Lazar Popovic24,** Orazio Caffo25, Sebastiano Buti26, Ravindran Kanesvaran27, Jindrich Kopecky28, Jakub Kucharz29, Annalisa Zeppellini30, Ondřej Fiala31,Johannes Landmesser32,Jawaher Ansari33,Patrizia Giannatempo34, Ignacio Ortego Zabalza9, **Fernando Sabino M. Monteiro35,36**, Nicola Battelli1, Fabio Calabrò37°, Camillo Porta22,38°

**°co-Senior Authors**

1Oncology Unit, Macerata Hospital, via Santa Lucia 2, 62100, Macerata, Italy; 2Markey Cancer Center, University of Kentucky, Lexington, KY, 40536-0293, USA; 3Department of Urology, University Hospital Bonn (UKB), 53127 Bonn, Germany; 4Department of Urology, Saitama Medical Center, Saitama Medical University, Saitama, Japan; 5University of Colorado Anschutz Medical Campus, Aurora, CO, USA; 6Department of Genitourinary Medical Oncology and Clinical Pharmacology, National Institute of Oncology, Budapest, Hungary; 7Department of Medical Oncology, Bakirköy Dr. Sadi Konuk Training and Research Hospital, Zuhuratbaba District, Tevfik Saglam St. No: 11, Bakirkoy, Istanbul, Turkey; 8Department of Urology, Medical University of Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria; 9Department of Medical Oncology, MD Anderson Cancer Center Madrid, Madrid, Spain; 10Southampton Experimental Cancer Medicine Centre, University of Southampton, Southampton, United Kingdom; 11Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni - 15, Bologna – Italia; 12UOC di Oncologia, Azienda Ospedaliera di Rilievo Nazionale Cardarelli di Napoli, Naples, Italy; 13Oncologia Medica, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy; 14Urologic Oncology, Champalimaud Clinical Center, 1400-038 Lisbon, Portugal; 15Medical Oncology 1 Unit, Department of Oncology, Istituto Oncologico Veneto IOV IRCCS, 35128 Padova, Italy; 16Department of Medical Oncology, Hospital Ramón y Cajal, Madrid, Spain; 17Oncology Unit 2, University Hospital of Pisa, Pisa 56126, Italy; 182nd Propaedeutic Dept of Internal Medicine, ATTIKON University Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece; 19Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy; 20Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy; 21Department of Oncology, IRCCS Humanitas Research Hospital, Rozzano - Milan, Italy; 22Division of Medical Oncology, A.O.U. Consorziale Policlinico di Bari, Piazza G. Cesare 11, 70124 Bari, Italy; 23Department of Medical Oncology, Centre Hospitalier de Jolimont, Haine Saint Paul, Belgium; 24Oncology Institute of Vojvodina, Faculty of Medicine, University Novi Sad, Novi Sad, Serbia; 25Medical Oncology Unit, Santa Chiara Hospital, Trento, Italy; 26Medical Oncology Unit, University Hospital of Parma – Department of Medicine and Surgery, University of Parma, Parma, Italy; 27Divisionof Medical Oncology, National Cancer Centre Singapore, Singapore; 28Department of Clinical Oncology and Radiotherapy, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic; 29Department of Uro-oncology, Maria Sklodowska-Curie National Research Institute of Oncology Warsaw, Poland; 30Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy; 31Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic; 32Klinik für Urologie, Ratzeburger Allee 160, 23538 Lübeck , Germany; 33Medical Oncology, Tawam Hospital, Al Ain, United Arab Emirates; 34Dipartimento di Oncologia Medica, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; 35Latin American Cooperative Oncology Group – LACOG; 36Oncology and Hematology Department, Hospital Santa Lucia, SHLS 716 Cj. C, Brasília, DF 70390-700, Brazil; 37Department of Oncology, San Camillo Forlanini Hospital, Rome, Italy; 38Chair of Oncology, Interdisciplinary Department of Medicine, University of Bari “Aldo Moro”, Bari, Italy.

**\*Correspondence to:**

Matteo Santoni, MD, PhD

Oncology Unit, Macerata Hospital, via Santa Lucia 2, 62100, Macerata, Italy. Phone number: +3907332572960; FAX number: +3907332573783; e-mail: mattymo@alice.it

**Abstract**

To be completed according to Journal Instructions.

**Keywords:** ARON-2 study; Immunotherapy; NCT05290038; Pembrolizumab; Real-world data; Survival; Tumor Response; Urothelial Cancer.

**Introduction**

The American Cancer Society has estimated 164,190 new cancer cases of the urinary system only in the United States in 2022 [1]. Approximately the 50% of these cases consist in tumors of the urinary bladder, which represents the 6% of all cancer diagnoses and the 4% of cancer-related deaths in men [1].

Urothelial cancer (UC) is the most prevalent histologic subtype of tumors of the upper and lower urinary tracts, accounting for approximately 90% of all cases [2]. About 25% of patients with UC present with metastatic disease, reporting a 5-year survival rate of only 7.7% [3].

In the past three decades, the management of first-line advancedUC has consisted in the administration of platinum-based chemotherapy [4]. The advent of immune-checkpoint inhibitors (ICIs) have challenged previous treatment paradigms of advanced UC in the post-platinum setting as well as in the first-line setting for cisplatin-ineligible patients [5,6], defined by the presence of at least one of the criteria published by Galsky *et al.*in 2011 [7]: (1) Eastern Cooperative Oncology Group (ECOG)-Performance Status (PS) of 2, (2) Creatinine clearance of less than 60 mL/minute, (3) Common Terminology Criteria for Adverse Events (CTCAE) of at least grade 2 hearing loss, (4) CTCAE of at least grade 2 neuropathy and (5) New York Heart Association Class III heart failure.

The approval of pembrolizumab by the Food and Drugs Adminitration (FDA) in cisplatin-unfit patients followed the results of the Keynote-052 phase 2 trial[8]. In this study, patients previously treated with prior systemic chemotherapy for unresectable or metastatic UC were excluded, while patients receiving platinum-based chemotherapy for tumor recurrence >12 months since completion of adjuvant or neoadjuvant therapy were eligible. The primary endpoint was objective response; 374 patients were enrolled; at a median follow-up of 5 months, Overall Response Rate (ORR) was 24%. In 2020, Vuky *et al.* [9] published the results of the long-term outcomes of patients included in the Keynote-052 study, with a minimum follow-up of 2 years. The ORR was 28.6%, with 8.9% of complete remissions, with median overall survival (OS) and duration of response of 11.3 months (95% CI, 9.7 to 13.1 months) and 30.1 months (95% CI, 18.1 months to not reached [NR]), respectively.

The ARON project was designed to globally share and analyze real-world data from patients with genitourinary tumors treated by immunotherapy. In particular, the ARON-2 study included UC patients receiving pembrolizumab as first or subsequent line therapy. In this study, we investigated the effectiveness of pembrolizumab as first-line treatment for cisplatin-ineligible patients affected by advanced UC.

**Patients and Methods**

*Study population*

The ARON-2 study retrospectively collected data from patients aged ≥18 years having a cytological and/or histological confirmed diagnosis of cisplatin-ineligible UC receiving first-line pembrolizumab (200 mg i.v. flat dose, every three weeks until clear radiological or clinical progression of disease) from January 1st 2017 to September 1st 2022. Cisplatin ineligibility was defined according to the Galsky criteria [7]. Thirty-three Institutions from 18 countries were involved in the ARON-2 study.

The ARON-2 dataset included clinical and laboratory data extracted from patients’ paper and electronic charts on age, gender, ECOG-PS, tumor histology, surgery, sites of metastases, and response to therapy were retrospectively collected. Patients with insufficient data on tumor response to therapy were not included in the ARON-2 study.

Computed tomography (CT) or magnetic resonance imaging (MRI) scans were performed following standard local procedures every 8–12 weeks. Physical and laboratory tests were usually carried out every 4–6 weeks during patients’ follow-up.

*Study endpoints*

The primary endpoint of the study was the effectiveness, assessed as ORR, duration of response (DoR), progression-free survival (PFS) and OS. Objective Response Rate (ORR) was calculated as the proportion of patients who achieved a complete (CR) or partial response (PR) defined by RECIST 1.1 criteria [10]. DoR was defined as the time from CR or PR to progression. Overall Survival (OS) was the time from treatment initiation to death from any cause. Progression-Free Survival (PFS) was calculated from the start of first-line pembrolizumab to progression or death from any cause, whichever occurred first. Patients without disease progression or death or lost at follow-up at the time of the analysis were censored at the last follow-up visit.

*Statistical Analysis*

The Kaplan-Meier statistical methods with Rothman’s 95% confidence intervals (CI) were used to estimate median OS, PFS and DoR. Cox proportional hazards models were used to compare the multivariable effects on patients’ survival and to calculate hazard ratios (HRs) and 95% CIs. Receiver operating characteristic (ROC) analysis was also used to understand the sensitivity and specificity profile and to identify potential cut-offs that better stratify patients in risk groups. The chi-square test was used to compare each group for categorical variables. Statistical differences were considered significant when the *p*-value was <0.05, and all *p* values were two-sided.

The upper tract was defined as the renal pelvis or ureter, and the lower tract as the bladder or urethra. Bajorin prognostic classification (including both the presence of visceral/bone metastases and Eastern Cooperative Oncology Group-Performance Status, ECOG-PS), was used to stratify patients according the number of risk factors [11].

MedCalc version 19.6.4 (MedCalc Software, Broekstraat 52, 9030 Mariakerke, Belgium) was used for the statistical analyses.) for all analyses. This study is registered with ClinicalTrials.gov, number NCT05290038.

**Results**

*Baseline characteristics*

Our analysis included 162 patients. The median follow-up time was 18.9 months (95%CI 15.3−76.9); 117 patients (74%) were males. Median age was 71y (range 43−94). ECOG-PS was ≥2 in 27 patients (17%). Tumors of the upper urinary tract accounted for the 16% of all cases. Tumor histology was pure UC in 142 patients (88%), squamous in 8 (5%), micropapillary in 3 (2%), glandular in 2 (1%), nested in 2 (1%), sarcomatoid in 2 (1%), undifferentiated in 2 (1%), and clear cell in 1 (1%). The 27% of patients presented metastatic disease at UC diagnosis. Lymph node and visceral metastases were identified in 112 (69%) and 90 (56%) patients, respectively. Stratifying by Bajorin prognostic classification [11], 63 patients (39%) presented 0 factors, 81 patients (50%) 1 factor and 18 patients (11%) both factors.

Seventy-three patients (45%) had died at time of the analysis. Treatment with pembrolizumab was ongoing in 74 patients (46%). Twenty-nine (33%) of the 88 patients progressed during first-line pembrolizumab were treated with second-line therapies. Patients’ baseline characteristics are summarized in Table 1.

*Overall Survival and Progression-Free Survival analyses*

In the overall study population, the median OS was 15.8 months (95%CI 11.3−32.4, Figure 1). The median OS was significantly longer in males vs females (21.2 months, 95%CI 12.3−45.9, vs 11.7 months, 95%CI 5.9−16.8, *p*=0.031, Figure 2). Otherwise, no statistically significant differences were observed between patients aged <65y vs ≥65y (16.8 months, 95%CI 10.5−45.9 vs 15.8 months, 95%CI 10.5−32.4, *p*=0.614) and between smokers and non-smokers (16.8 months, 95%CI 11.1−45.9, vs 13.4 months, 95%CI 8.8−29.4, *p*=0.594).

Patients with ECOG-PS ≥2 showed worst median OS compared to ECOG-PS 0-1 (7.4 months, 95%CI 6.1−14.3, vs 19.4 months, 95%CI 11.7−45.9, *p*=0.044, Figure 2).

Patients with pure UC histology showed a median OS of 16.8 months (95%CI 11.2−45.9), while in patients with mixed histology was 12.5 months (95%CI 3.3−32.4, *p*=0.438). Analogously, no statistically significant differences were found between patients with tumors of the upper tract (29.4 months, 95%CI 10.5−29.4) vs lower tract (14.3 months, 95%CI 11.1−33.4, *p*=0.160).

Metachronous metastatic disease was associated with longer median OS (19.4 months, 95%CI 11.3−45.9, vs 11.7 months, 95%CI 4.3−32.4, *p*=0.038, Figure 3). Patients with lymph node metastases only showed longer median OS compared to those with visceral metastases (29.4 months, 95%CI 13.4−45.9, vs 11.1 months, 95%CI 7.7−17.0, *p*=0.026, Figure 3). By stratifying patients according to sites of metastasis, a statistically significant difference was observed between patients with or without bone metastases (7.6 months, 95%CI 3.6−16.8, vs 21.2 months, 95%CI 12.5−45.9, *p*=0.016, Figure 3).

According to Bajorin risk factors [11], the median OS resulted 32.4 months (95%CI 15.8−45.9) in patients with 0 risk factors, 12.3 months (95%CI 7.7−17.0) in patients with 1 risk factor and 11.1 months (95%CI 1.7−14.3) in patients with 2 risk factors (*p*=0.019, Figure 3).

Furthermore, no significant differences were found between patients treated with first-line pembrolizumab who had received or not previous adjuvant or neoadjuvant chemotherapy (14.2 months, 95%CI 10.5−32.4, vs 17.0 months, 10.5−45.9, *p*=0.791).

In the overall study population, the median PFS was 10.2 months (95%CI 6.2−17.6, Figure 1). The median PFS was longer in males vs females, but the difference was not statistically significant (11.4 months, 95%CI 8.2−28.6, vs 5.1 months, 95%CI 2.7−26.3, *p*=0.155). Analogously, no statistically significant differences were observed between patients aged <65y vs ≥65y (9.0 months, 95%CI 6.2−36.7 vs 11.3 months, 95%CI 4.8−26.3, *p*=0.688), smokers vs non-smokers (9.1 months, 95%CI 6.2−17.0, vs 12.2 months, 95%CI 4.3−28.6, *p*=0.734), ECOG-PS≥2 vs <2 (9.3 months, 95%CI 1.9−15.2, vs 10.2 months, 95%CI 6.2−24.2, *p*=0.585), pure vs mixed UC histology (11.4 months, 95%CI 6.2−24.2, vs 4.8 months, 95%CI 2.0−13.4, *p*=0.111), upper vs lower urinary tract (18.6 months, 95%CI 2.2−28.6, vs 10.2 months, 95%CI 6.2−17.6, *p*=0.790), and previous adjuvant or neoadjuvant chemotherapy vs no previous treatments (7.5 months, 95%CI 4.8−11.3, vs 15.2 months, 6.6−28.6, *p*=0.120).

Synchronous metastatic disease was associated with shorter median PFS (5.3 months, 95%CI 2.3−11.7, vs 11.7 months, 95%CI 7.5−28.6, *p*=0.017, Figure 4). Patients with lymph node metastases only showed longer median PFS compared to those with visceral metastases (26.3 months, 95%CI 11.3−33.7, vs 5.5 months, 95%CI 3.8−9.1, *p*=0.002, Figure 4). By stratifying patients according to sites of metastasis, patients with bone metastases showed a significantly shorter median PFS (3.4 months, 95%CI 1.9−5.5, vs 17.0 months, 95%CI 9.4−28.6, *p*<0.001, Figure 4).

Finally, according to Bajorin risk classification, the median PFS resulted 26.3 months (95%CI 9.4−33.7) in patients with 0 risk factors, 8.6 months (95%CI 5.1−17.0) in patients with 1 risk factor and 4.8 months (95%CI 1.2−13.4) in patients with 2 risk factors (*p*=0.022, Figure 4).

*Response to therapy*

According to Recist 1.1 criteria, 26 patients (16%) experienced CR, 32 (20%) PR, 39 (24%) SD and 55 (34%) PD. Patients with 0, 1 or 2 Bajorin risk factors showed an ORR of 43%, 33%, and 22%, respectively (*p*=0.007).

The median OS resulted significantly different according to the type of response, being NR (95%CI NR−NR), 45.9 months (95%CI 17.0−45.9), 13.4 months (95%CI 7.4−19.4) and 6.4 months (95%CI 2.9−21.2) in patients with CR, PR, SD, and PD, respectively (*p*<0.001, Figure 5). In the 58 patients who presented CR or PR, 44 were still ongoing at time of the analysis. The median DoR was NR (95%CI NR−NR).

*Role of prognostic factors*

At univariate analysis, gender, synchronous metastatic disease and Bajorin risk classification were significant predictors of OS, and their prognostic role was confirmed at multivariate analysis (Table 2).

Furthermore, IMDC group, synchronous metastatic disease and Bajorin risk classification significantly correlated with PFS at univariate analysis, although only Bajorin risk factors proved to be associated with PFS at multivariate analysis (Table 2).

**Discussion**

Cisplatin-unfit patients represent at least 30–40% of patients with metastatic UC [12]. Owing to a median age at diagnosis of 70 years, and being smoking an associated risk factor, many patients have pulmonary and/or cardiovascular diseases that lead to an accelerated deterioration of renal function. Age-related decrease in glomerular filtration rate impairs the patients’ possibility to receive cisplatin, as well as impaired ECOG-PS.

A randomized EORTC study [13] comparing M-CAVI and gemcitabine plus carboplatin in patients cisplatin-unfit not only proved acceptable Response Rate of the gemcitabine plus carboplatin arm (38%), but also supported the importance of stratification parameters and Bajorin risk groups on RR. Indeed, patients with 0, 1 or 2 Bajorin risk factors showed a RR of 47%, 39% and 20%, respectively.

More recently, Martini *et al.* [14] led a meta-analysis to compare chemotherapy and immunotherapy in the first-line setting of advanced UC. They observed no OS benefit for patients treated with first-line immune checkpoint inhibition compared to chemotherapy among the overall population, cisplatin-ineligible patients, and PD-L1-high patients.

The ARON-2 study was designed to assess the effectiveness of pembrolizumab as first or successive line therapy in patients with advanced UC and the presence of factors influencing the prognosis of these patients. In this sub-analysis, we focused on the efficacy of pembrolizumab in the first-line setting of patients unable to receive cisplatin. We showed that median OS and PFS were 15.8 and 10.2 months, respectively. The presence of synchronous metastatic disease, visceral or bone metastases and a higher number of Bajorin risk factors were significantly associated with worst OS and PFS. The ORR was 36% with 16% of CR and type of tumor response according to RECIST 1.1 criteria was a significant predictor of OS.

Our results in terms of both OS and PFS are more favorable than those previously published in the Keynote-052 study investigating pembrolizumab in the same context. This difference can be explained by the presence of a lower percentage of patients with ECOG-PS≥2 (17% vs 42%) and visceral metastases (56% vs 85%) included in the ARON-2 study population. This means that in our population we have 83% of patients considered cisplatin unfit due to reasons other than PS (i.e. renal failure, hearing loss, neuropathy and heart failure), probably reflecting better the population in real life who need first-line treatment in this setting. Of note, the recent presentation of novel cisplatin-unfit criteria at ASCO 2022 [15] may influence the selection of patients candidate to receive first-line pembrolizumab and should be prospectively investigated.

Our study presents several limitations, mainly due to its retrospective nature. We had no available data neither on the criteria of eligibility of cisplatin-unfit patients nor on concomitant medication or other comorbidities that could affect the efficacy of first-line therapy. As a consequence, our results should be interpreted with caution and are in need of a larger prospective validation.

Despite a centralized review of radiological imaging was not performed, the strong correlation between response and OS suggests a reliable assessment of RECIST 1.1 in the present study.

Nevertheless, our data show that pembrolizumab was effective as first-line therapy for cisplatin-unfit patients. Further studies investigating the biological and immunological characteristics of UC patients are warranted in order to optimize the outcome of patients receiving immunotherapy in this setting.

**Conflicts of Interest**

Matteo Santoni has received research support and honoraria from Janssen, Bristol Myers Squibb, Ipsen, MSD, Astellas and Bayer, all unrelated to the present paper.

R. Kanesvaran has received fees for speaker bureau and advisory board activities from the following companies; Pfizer, MSD, BMS, Eisai, Ipsen, Johnson and Johnson, Merck, Amgen, Astellas and Bayer.

Enrique Grande has received honoraria for speaker engagements, advisory roles or funding of continuous medical education from Adacap, AMGEN, Angelini, Astellas, Astra Zeneca, Bayer, Blueprint, Bristol Myers Squibb, Caris Life Sciences, Celgene, Clovis-Oncology, Eisai, Eusa Pharma, Genetracer, Guardant Health, HRA-Pharma, IPSEN, ITM-Radiopharma, Janssen, Lexicon, Lilly, Merck KGaA, MSD, Nanostring Technologies, Natera, Novartis, ONCODNA (Biosequence), Palex, Pharmamar, Pierre Fabre, Pfizer, Roche, Sanofi-Genzyme, Servier, Taiho, and Thermo Fisher Scientific. EG has received research grants from Pfizer, Astra Zeneca, Astellas, and Lexicon Pharmaceuticals

Fernando Sabino Marques Monteiro has received research support from Janssen, Merck Sharp Dome and honoraria from Janssen, Ipsen, Bristol Myers Squibb and Merck Sharp Dome.

Camillo Porta has received honoraria from Angelini Pharma, AstraZeneca, BMS, Eisai, General Electric, Ipsen and MSD and acted as a Protocol Steering Committee Member for BMS, Eisai and MSD.

Sebastiano Buti received honoraria as speaker at scientific events and advisory role by BMS, Pfizer, MSD, Ipsen, AstraZeneca, Merck.

Patrizia Giannatempo has received research support from Ipsen, Astra Zeneca e MSD and honoraria for speaker engagements, advisory roles from Astellas, MSD, Janssen, Pfizer.

The other authors declare to have no conflicts of interest.

**Fundings**

None to declare.

**References**

1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Cl in. 2022;72(1):7-33.
2. Mohanty SK, Lobo A, Cheng L. The 2022 revision of World Health Organization classification of tumors of the urinary system and male genital organs: advances and challenges. Hum Pathol. 2022:S0046-8177(22)00224-6.
3. Cronin KA, Lake AJ, Scott S, Sherman RL, Noone AM, Howlader N, et al. Annual report to the Nation on the status of cancer, part I: National cancer statistics. Cancer 124(13): 2785-2800
4. Galsky MD, Chen GJ, Oh WK, Bellmunt J, Roth BJ, Petrioli R, Dogliotti L, Dreicer R, Sonpavde G. Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. Ann Oncol 2012;23(2):406-10..
5. Mollica V, Rizzo A, Montironi R, Cheng L, Giunchi F, Schiavina R, Santoni M, Fiorentino M, Lopez-Beltran A, Brunocilla E, Brandi G, Massari F. Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma. Cancers (Basel) 2020;12(6):1449.
6. Powles T, Smith K, Stenzl A, Bedke J. Immune checkpoint inhibition in metastatic urothelial cancer. Eur Urol 2017;72:477–481.
7. Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, et al. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol 2011;12(3):211-4.
8. Balar AV, Castellano D, O'Donnell PH, Grivas P, Vuky J, Powles T, Plimack ER, Hahn NM, de Wit R, Pang L, Savage MJ, Perini RF, Keefe SM, Bajorin D, Bellmunt J. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol 2017;18(11):1483-1492.
9. Vuky J, Balar AV, Castellano D, O'Donnell PH, Grivas P, Bellmunt J, et al. Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients with Locally Advanced or Metastatic Urothelial Cancer. J Clin Oncol 2020;38(23):2658-2666.
10. Schwartz LH, Litière S, de Vries E, Ford R, Gwyther S, Mandrekar S, et al. RECIST 1.1-Update and clarification: From the RECIST committee. Eur J Cancer 2016; 62:132-7.
11. Bajorin DF, Dodd PM, Mazumdar M, Fazzari M, McCaffrey JA, Scher HI, et al. Long-term survival in metastatic transitional-cellcarcinoma and prognostic factors predicting outcomeof therapy. J Clin Oncol 1999;17(10):3173-81.
12. de Wit R. Overview of bladder cancer trials in the European Organization for Research and Treatment. Cancer 2003;97:2120–26.
13. de Santis M, Bellmunt J, Mead G, Kerst M, Leahy M, Maroto P, et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer ‘unfit’ for cisplatin-basedchemotherapy: phase II – results of EORTC study 30986. J Clin Oncol 2009;27:5634–9.
14. Martini A, Raggi D, Fallara G, Nocera L, Schultz JG, Belladelli F, et al. Immunotherapy versus chemotherapy as first-line treatment for advanced urothelial cancer: A systematic review and meta-analysis. Cancer Treat Rev. 2022;104:102360.
15. Gupta S, Bellmunt J, Plimack ER, Sonpavde GP, Grivas P, Apolo AB. Defining “platinum-ineligible” patients with metastatic urothelial cancer (mUC). J Clin Oncol 2022; 40;4577-4577.

**Table Legends**

**Table 1.** Patients’ characteristics.

|  |  |
| --- | --- |
|  | Patients  (n=162) |
| Sex  Male  Female | 117 (72)  45 (28) |
| Age, years (y)  Median  Range | 71  43−94 |
| ECOG Performance Status  0  1  2  3 | 53 (33)  81 (50)  25 (16)  2 (1) |
| Current or former smokers | 114 (70) |
| Primary tumour location  Upper urinary tract  Lower urinary tract | 26 (16)  136 (84) |
| Tumor histology  Pure urothelial carcinoma  Variants | 142 (88)  20 (12) |
| Metastatic disease  Sinchronous  Metachronous | 44 (27)  119 (73) |
| Common sites of metastasis  Lymph nodes  Lung  Liver  Bone  Brain | 112 (69)  40 (25)  21 (13)  40 (25)  3 (2) |
| Visceral metastases  Yes  No | 90 (56)  72 (44) |
| Previous adjuvant or neoadjuvant platinum based chemotherapy | 62 (38) |
| Second-line therapy  Carboplatin + Gemcitabine  Vinflunine  Paclitaxel  Gemcitabine  Enfortumab vedotin  Clinical trials | 10 (6)  5 (3)  5 (3)  2 (1)  2 (1)  5 (3) |

**Table 2.** Univariate and Multivariate analyses of predictors of Progression-Free Survival and Overall Survival in cisplatin-unfit UC patients treated with first-line pembrolizumab. Statistically significant values were reported in bold.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Overall Survival** | **Univariate Cox Regression** | | **Multivariable Cox regression** | |
| **HR (95%CI)** | ***p-value*** | **HR (95%CI)** | ***p-value*** |
| Gender (females vs males) | 1.68 (1.04−2.72) | **0.033** | 1.71 (1.05−2.77) | **0.031** |
| Age (≥65y vs <65y) | 1.14 (0.69−1.86) | 0.614 |  |  |
| Smokers vs no-smokers | 0.88 (0.54−1.43) | 0.876 |  |  |
| Histology (mixed vs pure UC) | 1.30 (0.67−2.54) | 0.440 |  |  |
| Upper vs Lower urinary tract | 0.59 (0.28−1.24) | 0.165 |  |  |
| Synchronous metastatic disease (yes vs no) | 1.94 (1.20−3.15) | **0.007** | 1.61 (0.97−2.66) | **0.048** |
| Bajorin risk factors | 1.66 (1.16−2.37) | **0.005** | 1.57 (1.09−2.24) | **0.014** |
| Previous neoadjuvant or adjuvant chemotherapy | 1.07 (0.66−1.71) | 0.791 |  |  |
|  | | | | |
| **Progression-Free Survival** | **Univariate Cox Regression** | | **Multivariable Cox regression** | |
| **HR (95%CI)** | ***p-value*** | **HR (95%CI)** | ***p-value*** |
| Gender (females vs males) | 1.38 (0.88−2.18) | 0.161 |  |  |
| Age (≥65y vs <65y) | 1.10 (0.70−1.73) | 0.691 |  |  |
| Smokers vs no-smokers | 1.09 (0.68−1.74) | 0.725 |  |  |
| Histology (mixed vs pure UC) | 1.56 (0.90−2.73) | 0.115 |  |  |
| Upper vs Lower urinary tract | 0.92 (0.51−1.66) | 0.790 |  |  |
| Synchronous metastatic disease (yes vs no) | 1.71 (1.09−2.67) | **0.019** | 1.49 (0.93−2.37) | 0.094 |
| Bajorin risk factors | 1.55 (1.12−2.13) | **0.007** | 1.43 (1.03−1.98) | **0.033** |
| Previous neoadjuvant or adjuvant chemotherapy | 1.40 (0.91−2.14) | 0.122 |  |  |
| ECOG-PS = Eastern Cooperative Oncology Group-Performance Status; UC = Urothelial Carcinoma | | | | |

**Figure Legends**

**Figure 1.** Median Overall Survival and Progression-Free Survival in cisplatin-unfit UC patients treated with first-line pembrolizumab.

**Figure 1.tif**

**Figure 2.** Median Overall Survival in cisplatin-unfit UC patients treated with first-line pembrolizumab stratified by sex and ECOG-PS.

Figure 2.tif

**Figure 3.** Median Overall Survival in cisplatin-unfit UC patients treated with first-line pembrolizumab stratified by synchronous or metachronous metastatic disease, visceral metastases, bone metastases and Bajorin risk classification.

**Figure 3.tif**

**Figure 4.** Median Progression-Free Survival in cisplatin-unfit UC patients treated with first-line pembrolizumab stratified by synchronous or metachronous metastatic disease, visceral metastases, bone metastases and Bajorin risk classification.

**Figure 4.tif**

**Figure 5.** Overall Survival by tumor response to therapy (RECIST 1.1).

**Figure 5.tif**